Mastocytosis: the safety of different COVID-19 vaccines
Mastocitose: segurança de diferentes vacinas contra a COVID-19
Inês Nunes; Beatriz Tavares; Emília Faria; Francisca Cunha Tavares; Pedro Botelho Alves; Iolanda Alen Coutinho; Carmelita Ribeiro; Graça Loureiro; Ana Todo-Bom
Abstract
The COVID-19 pandemic has forced the development of vaccines to fight SARS-CoV-2. After vaccination began, reports of adverse reactions, including anaphylaxis, emerged. This raised concerns about the safety of COVID-19 vaccines in patients diagnosed with mastocytosis. The authors share their experience in administering different COVID-19 vaccines to patients diagnosed with mastocytosis.
Keywords
Resumo
A pandemia por COVID-19 obrigou ao rápido desenvolvimento de vacinas para combate ao SARS-CoV-2. Após o início da vacinação começaram a surgir relatos de reações adversas às vacinas, incluindo reações anafiláticas, surgindo dúvidas sobre a segurança das vacinas em doentes com mastocitose. Os autores apresentam a sua experiência em relação à administração de diferentes vacinas contra a COVID-19 em doentes com diagnóstico de mastocitose.
Palavras-chave
References
1. Banerji A, Wickner PG, Saff R, Stone CA Jr, Robinson LB, Long AA, et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. J Allergy Clin Immunol Pract. 2021;9(4):1423-37. doi: 10.1016/j. jaip.2020.12.047.
2. Klimek L, Jutel M, Akdis CA, Bousquet J, Akdis M, Torres MJ, et al. ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – An EAACI-ARIA Position Paper. Allergy Eur J Allergy Clin Immunol. 2021;76(6):1624-8. doi: 10.1111/all.14726.
3. Bonadonna P, Pagani M, Aberer W, Bilò MB, Brockow K, Oude Elberink H, et al. Drug hypersensitivity in clonal mast cell disorders: ENDA/EAACI position paper. Allergy Eur J Allergy Clin Immunol. 2015;70(7):755-63. doi: 10.1111/all.12617.
4. Zanoni G, Zanotti R, Schena D, Sabbadini C, Opri R, Bonadonna P. Vaccination management in children and adults with mastocytosis. Clin Exp Allergy. 2017;47:593-6. doi: 10.1111/cea.12882.
5. Valent P, Akin C, Bonadonna P, Brockow K, Niedoszytko M, Nedoszytko B, et al. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. J Allergy Clin Immunol. 2020;146(2):300-6. doi: 10.1016/j.jaci.2020.06.009.
6. Bonadonna P, Brockow K, Niedoszytko M, Elberink HO, Akin C, Nedoszytko B, et al. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). J Allergy Clin Immunol Pract. 2021;9(6):2139-44. doi: 10.1016/j.jaip.2021.03.041.
7. Rama TA, Moreira A, Castells M. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis. J Allergy Clin Immunol. 2021 Mar;147(3):877-8. doi: 10.1016/j. jaci.2021.01.004.
8. Kaakati R, Khokhar D, Akin C. Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome. J Allergy Clin Immunol Pract. 2021;9(8):3198-9. doi: 10.1016/j.jaip.2021.05.010.
9. Ruano-Zaragoza M, Carpio-Escalona LV, Diaz-Beya M, PirisVillaespesa M, Castaño-Diez S, Muñoz-Cano R, et al. Safety of COVID-19 vaccination in patients with clonal mast cell disorders. J Allergy Clin Immunol Pract. 2022 May;10(5):1374-6.e3. doi: 10.1016/j.jaip.2022.01.030.
10. Lazarinis N, Bossios A, Gülen T. COVID-19 vaccination in the setting of mastocytosis-Pfizer-BioNTech mRNA vaccine is safe and well tolerated. J Allergy Clin Immunol Pract. 2022 May;10(5):1377-9. doi: 10.1016/j.jaip.2022.01.037.
11. Tuncay G, Bostan OC, Damadoglu E, Karakaya G, Kalyoncu AF. SARS-CoV-2 vaccines are well tolerated in patients with mastocytosis. Ann Allergy Asthma Immunol. 2022 Mar 4:S1081- 1206(22)00172-7. doi: 10.1016/j.anai.2022.02.026.
12. Rama TA, Álvarez-Twose I. Delving into covid-19 vaccination – induced anaphylaxis: Are mRNA vaccines safe in mast cell disorders? J Investig Allergol Clin Immunol. 2021;31(2):193-5. doi: 10.18176/ jiaci.0680.
Submitted date:
08/13/2022
Accepted date:
09/16/2022
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email